Clinical trials: Platelet Abnormality
Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
Hemolytic Uremic Syndrome (HUS) is a foodborne disease which mainly affects children. It is caused by Escherichia coli bacteria, which release a toxin called Shiga toxin within the body.
- Conditions
- Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease, Hemolytic-Uremic Syndrome
- Trial name
- NCT05569746
- Testing
- INM004, SoC
- Where
- 16 sites in Argentina
- Volunteers
- 57 people
- Sponsor
- Inmunova S.A.
Massive Hemorrhage, Massive Blood Loss
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia
This is a retrospective descriptive study, to study the treatment indications, changes in transfusion need, coagulation profiles changes and clinical outcome (survival, complication) of non-haemophiliac patients who received…
- Conditions
- Massive Hemorrhage, Massive Blood Loss, Massive Blood Transfusion; Thrombocytopenia
- Trial name
- NCT03251547
- Testing
- NovoSeven
- Where
- Malaysia
- Volunteers
- 76 people
- Sponsor
- Universiti Sains Malaysia
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myeloproliferative Neoplasms
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a…
- Trial name
- NCT05936359
- Testing
- INCA033989, Ruxolitinib
- Where
- 28 sites in Australia, Canada and 7 more
- Volunteers
- 160 people
- Sponsor
- Incyte Corporation
Primary Immune Thrombocytopenia
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.
- Trial name
- ADVANCE (NCT04188379)
- Testing
- efgartigimod
- Where
- 121 sites in United States, Austria and 16 more
- Volunteers
- 131 people
- Sponsor
- argenx
ITP - Immune Thrombocytopenia
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed…
- Trial name
- RPE-ITP (NCT06790888)
- Testing
- Ripertamab/Eltrombopag, Eltrombopag
- Volunteers
- 78 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chemotherapy-Induced Thrombocytopenia
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two…
- Trial name
- NCT01345214
- Testing
- ONO-7746
- Where
- 14 sites in United States, Russia and 1 more
- Volunteers
- 17 people
- Sponsor
- Ono Pharma USA Inc
Immune Thrombocytopenic Purpura
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
This is a study to investigate if eltrombopag can be used instead of Intravenous Immune Globulin (IVIG) in patients with ITP, to adequately raise their platelet count when they undergo minor or major surgery.
- Trial name
- NCT01621204
- Testing
- Eltrombopag, IVIG infusion
- Where
- 10 sites in Canada, Netherlands
- Volunteers
- 74 people
- Sponsor
- McMaster University
Myelofibrosis, Idiopathic Myelofibrosis
Research Tissue Bank
This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: Peripheral blood Bone marrow Bone marrow biopsy A phlebotomized unit of blood Spleen cells Toenail clippings…
- Conditions
- Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT00666549
- Where
- 11 sites in United States, Italy
- Volunteers
- 963 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Immune Thrombocytopenia
An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP
The aim of this study is to evaluate the efficacy of romiplostim administered at every other week in ITP patients who attained stable platelet counts ≥ 50 x 109/L for 4 consecutive weeks after weekly doses of romiplostim.
- Trial name
- NCT02338414
- Testing
- Romiplostim
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Purpura, Thrombocytopenic, Idiopathic, Regulatory B Cells
Regulatory B Cells and Chronic Immune Thrombocytopenia
The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells.
- Trial name
- PTIREG (NCT02891109)
- Testing
- Biological tests
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Chorioamnionitis, Placenta Diseases
Effect of Chorioamnionitis on Platelet Activation and Placental Vessel Among Preterm Infants by Wnt-Flt1 Signal Pathway
Objective:The purpose of this study was to explore the effect and mechanism of maternal chorioamnionitis on placental microvasculature and platelet activation among preterm infants by activating Wnt-Flt1 signal pathway .
- Conditions
- Chorioamnionitis, Placenta Diseases, Thrombocytopenia, Preterm Infant
- Trial name
- NCT03636698
- Testing
- chorioamnionitis
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Women and Children Hospital
Immune Thrombocytopenia
The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia
A randomized, open-label, multicenter study to compare the efficacy and safety of terbutaline plus danazol compared to danazol monotherapy for the second-line treatment of adults with corticosteroid-resistant or relapsed primary…
- Trial name
- NCT05494307
- Testing
- Terbutaline, Danazol
- Volunteers
- 228 people
- Sponsor
- Peking University People's Hospital
Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenia
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
The project was undertaking by Qilu Hospital of Shandong University and other 18 well-known hospitals in China. In order to report the efficacy and safety of decitabine combining with dexamethasone for the treatment of adults…
- Trial name
- NCT03252457
- Testing
- Decitabine, Dexamethasone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong University
Thrombopenia
Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation.
About 40 % of the patients in reanimation are thrombopenics and the causes are not well known (reduction in platelet's production, increase in their destruction...).
- Trial name
- NCT00336687
- Where
- France
- Volunteers
- 322 people
- Sponsor
- University Hospital, Clermont-Ferrand
HIV Infections, Primary Health Care
HIV Indicator Diseases in Hospital and Primary Care
Patients are frequently evaluated by physicians for medical work-up of HIV indicator conditions in hospital and in primary care at the general practitioner.
- Conditions
- HIV Infections, Primary Health Care, Acquired Immunodeficiency Syndrome, Sexually Transmitted Diseases, Viral
- Trial name
- #AwareHIV (NCT05225493)
- Testing
- Peer to peer feedback, HIV rapid test
- Where
- Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Erasmus Medical Center
Severe Neutropenia, Thrombocytopenia
Effect of Supragingival Irrigators Containing Chlorhexidine on Oral Health in Blood Dyscrasia
in this study , effectiveness of supragingival irrigators containing chlorhexidine is compared with routine oral health measures in patients with blood dyscrasia whom can not use effective oral health measures(e.g brushing ) due…
- Conditions
- Severe Neutropenia, Thrombocytopenia, Chemotherapy, Blood Dyscrasia Patients
- Trial name
- NCT01974401
- Testing
- supragingival irrigators containing chlorhexidine
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Mashhad University of Medical Sciences
Hepatitis C, Chronic, Hepatitis C
SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 as a treatment for patients with chronic…
- Conditions
- Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
- Trial name
- NCT00110799
- Testing
- SB497115
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Myelodysplastic Neoplasm, Myelodysplastic Syndrome
Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms
Hypocellular myelodysplastic neoplasms (h-MDS) are a distinct entity introduced in the 2022 WHO classification. They are characterized by reduced bone marrow cellularity and may share several clinical, morphological…
- Trial name
- NCT07825207
- Testing
- Eltrombopag (ELT)
- Where
- 26 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
Idiopathic Thrombocytopenic Purpura
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study.
- Trial name
- PETIT2 (NCT01520909)
- Testing
- Eltrombopag
- Where
- 51 sites in United States, Argentina and 11 more
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline